2022 Press Releases 2025 2024 2023 2022 2021 Portfolio Companies New Leaf Portfolio Companies Rallybio Announces Publication of Data Highlighting the Ability of HPA-1a-Specific Antibodies to Prevent Alloimmunization in an Authentic Mouse Model of FNAITDecember 15, 2022 Iterum Therapeutics announces Issuance of Allowance for a U.S. Patent Covering Oral SulopenemDecember 15, 2022 PASSAGE BIO ANNOUNCES POSITIVE INTERIM CLINICAL DATA FROM FIRST SIX PATIENTS WITH GM1 GANGLIOSIDOSIS IN IMAGINE-1 STUDYDecember 14, 2022 HARPOON THERAPEUTICS PRESENTS UPDATED INTERIM RESULTS AT ASH 2022 FOR NOVEL T CELL ENGAGER HPN217 IN RELAPSED/REFRACTORY MULTIPLE MYELOMAsDecember 11, 2022 Medication Intelligence Leader Kit CheckⓇ Rebrands as BluesightⓇDecember 5, 2022 AbCellera and Rallybio Announce Strategic Alliance to Discover, Develop, and Commercialize Novel Antibody-Based Therapeutics for Rare DiseasesDecember 1, 2022 Arvinas Announces ARV-471 Achieves a Clinical Benefit Rate of 38% in Evaluable Patients and Continues to Show a Favorable Tolerability Profile in its Phase 2 Expansion Trial (VERITAC)November 22, 2022 Cleerly Partners With Heartbeat Health for Increased Access to Early Cardiac EvaluationsNovember 17, 2022 BrightInsight Ranked 217th Fastest-Growing Company in North America on the 2022 Deloitte Technology Fast 500™November 16, 2022 BrightInsight Inks Enterprise Agreement with CSL Behring for Digital Health Solutions Across Brand PortfolioNovember 14, 2022 Rallybio Announces Pricing of $50 Million Public OfferingNovember 10, 2022 Cleerly’s Proxy solution improves heart disease imaging workflowsOctober 31, 2022 Glympse to Present Data Demonstrating Sensitive Detection of Hepatocellular Carcinoma at AASLD The Liver Meeting 2022October 25, 2022 Iterum Announces First Patient Dosed in REASSURE, a Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract InfectionsOctober 20, 2022 BrightInsight Adds Xealth, Woebot Health and Claritas Rx to the BrightInsight EcosystemSeptember 27, 2022 Deciphera Pharmaceuticals, Inc. Announces Publication of INTRIGUE Phase 3 Clinical Study Results in Journal of Clinical OncologyAugust 10, 2022 Heart Health Innovator Cleerly Closes Series C Funding Round with $223 MillionJuly 25, 2022 Iterum Therapeutics Announces Special Protocol Assessment (SPA) Agreement With the FDAJuly 11, 2022 Kyruus Announces Paul Merrild as Company’s First PresidentJune 29, 2022 TigerConnect Appoints Melissa Bell Company’s First PresidentJune 16, 2022 Kyruus Wins Google Cloud Healthcare & Life Sciences 2021 Customer AwardJune 14, 2022 Kit Check Recognized as Industry-Leading Vendor for Kit and Tray Management.June 10, 2022 Cogent Biosciences Announces Positive Initial Clinical Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)June 10, 2022 Glympse to Present Two Posters Demonstrating Novel Protease Biosensor Diagnostic Platform Detection of Hepatocellular Carcinom at EASL ILC 2022June 8, 2022 Qlaris Bio Reports Phase 2 Clinical Trial Results Demonstrating Favorable Safety and Tolerability Profile and Positive Efficacy Signal for QLS-101May 18, 2022 Rallybio Announces In-Licensing of Potential First-In-Class Preclinical Antibody Candidate from SanofiMay 10, 2022 Kyruus and Upfront Partner to Enable Healthcare Organizations to Maximize Digital Patient Acquisition and RetentionApril 21, 2022 GSK Reaches Agreement to Acquire Late-Stage Biopharmaceutical Company Sierra Oncology For $1.9bnApril 13, 2022 Deciphera Pharmaceuticals Presents Preclinical Data from DCC-3116 Program at the AACR Annual MeetingApril 12, 2022 Pfizer to Acquire ReViral and Its Respiratory Syncytial Virus Therapeutic CandidatesApril 7, 2022 PASSAGE BIO ANNOUNCES PUBLICATION OF PRECLINICAL DATA THAT SUPPORT ONGOING CLINICAL STUDY OF PBKR03 IN KRABBE DISEASEMarch 29, 2022 PASSAGE BIO PROVIDES UPDATE ON STRATEGIC PRIORITIES AND EXTENDS CASH RUNWAYMarch 15, 2022 WellHive Announces Partnership with Kyruus to Integrate Systems and Optimize Care Navigation for VeteranMarch 10, 2022 UPMC and Kyruus Launch Strategic Partnership to Transform Digital Patient Access and Care NavigationMarch 9, 2022 BrightInsight and UCB Partner to Build Digital Care Solutions for Rare DiseasesMarch 8, 2022 Star Therapeutics emerges from stealth mode raising $100M in financing since inception to be an innovation engine for rare disease therapiesFebruary 16, 2022 Electra Therapeutics announces $84 million Series B financing and unveils its novel SIRP targeted therapies for immunological diseases and cancerFebruary 16, 2022 Arvinas Announces New Data from Completed Phase 1 Dose Escalation and Ongoing Phase 2 ARDENT Expansion Cohort with Novel PROTAC® Degrader Bavdegalutamide (ARV-110) to be Presented at 2022 ASCO GU MeetingFebruary 14, 2022 Kit Check’s Bluesight® for Controlled Substances is Named Best in KLAS for the 3rd Consecutive YearFebruary 8, 2022 CLEERLY TAKES PRECISION HEART CARE TO THE NEXT LEVEL WITH CLEERLY 2.2.0February 8, 2022 Kyruus Announces Record-Breaking Customer Growth in 2021, Welcoming HealthSparq and Connecting Millions of People with CareFebruary 3, 2022 CLEERLY NAMED TO NYC DIGITAL HEALTH 100 BY NEW YORK CITY HEALTH BUSINESS LEADERSFebruary 2, 2022 PDS Biotech Announces Preclinical Data for PDS0202 Universal Influenza VaccineJanuary 27, 2022 Sierra Oncology Announces Pricing of Upsized Public Offering of SecuritiesJanuary 26, 2022 Sierra Oncology Announces Momelotinib Achieved Statistically Significant Benefit on Symptoms, Anemia and Splenic Size in the Pivotal MOMENTUM Study for MyelofibrosisJanuary 25, 2022 Kit Check Launches Webinar Series Focused on RFID Innovation in HealthcareJanuary 20, 2022 Atlantic Health System Takes Consumer Convenience to the Next Level with Online Scheduling from KyruusJanuary 12, 2022 State of Minnesota Selects Truveris to Help Optimize its Pharmacy Benefits ProgramJanuary 12, 2022 TigerConnect Secures Strategic Growth Investment from Vista Equity PartnersJanuary 11, 2022 BrightInsight Announces Partnership with Sanofi to Bring to Market a Next Generation Digital Companion ApplicationJanuary 10, 2022 Edgewise Therapeutics Announces Positive Topline Results From the EDG-5506 Phase 1b Clinical Trial in Adults With Becker Muscular Dystrophy (BMD)January 5, 2022
